
Supplementary Materials

# Supplementary Figures



**Supplementary Figure 1.** Contraction of primary human fibroblasts with addition of pirfenidone. Areas are normalized to the initial area of each microgel. N=1-2 per condition.

A close up of a map

Description automatically generated

**Supplementary Figure 2.** Contraction of collagen microgels by primary human lung fibroblasts with addition of nintedanib. Areas of collagen microgels were normalized to their initial area. N=1-2 per condition.

A picture containing text, map

Description automatically generated

**Supplementary Figure 3.** Contraction of collagen microgels with primary human lung fibroblasts and the FAK inhibitor, PF 431396. Areas are normalized to the initial area of each microgel. N=1-2 per condition.

**A close up of a piece of paper

Description automatically generatedSupplementary Figure 4.** Fitted values for IC50 for each cell and TGF-β1 combination, graphed over individual time points. Error bars are standard deviation, calculated from the model fit covariance.

**Supplementary Table 1.** Fitted IC50 values for cell, stimulant, and drug combinations.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **NHLF IC50 (μM)** | |  | **IPF IC50 (μM)** | |
| **Drug** | **-TGF-β1** | **+TGF-β1** |  | **-TGF-β1** | **+TGF-β1** |
| PF 431396 | 6.32.5 | 10.210.7 |  | 9.8 3.6 | 11.54.3 |
| Nintedanib | 5.93.0 | 12.9 4.1 |  | 47.123.9 | 43.115.2 |
| Pirfenidone | >500.0 | >500.0 |  | >500.0 | >500.0 |